Data as of Q4 2025 (Dec 31, 2025)

Belite Bio, Inc

(BLTE)

Financial Statements · SEC EDGAR XBRL

Net Income
-$77.6M
-114.7%
EPS
$-2.31
-95.8%
Op. Income
-$84.2M
-110.5%
FCF
-$37.1M
-26.3%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Operating Expenses & Income
Selling General & Admin
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Interest Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
$38.8M
$10.1M
$6.8M
-
-
$45.4M
$29.9M
$24.8M
$8.9M
$7.4M
$84.2M
$40.0M
$31.7M
$12.8M
$9.8M
-$84.2M
-$40.0M
-$31.7M
-$12.8M
-$9.8M
-
-
$25K
$16K
-
$6.6M
$3.9M
$45K
$173K
$131K
-$77.6M
-$36.1M
-$31.6M
-$12.6M
-$9.7M
$0
$6K
$9K
-
-
-$77.6M
-$36.1M
-$31.6M
-$12.6M
-$9.7M
$-2.31
$-1.18
$-1.19
$-0.63
$-1.01
$-2.31
$-1.18
$-1.19
$-0.63
$-1.01
33.5M
30.5M
26.6M
20.0M
9.6M